The global pandemic brought mainstream media attention to the process of taking a pharmaceutical drug from pre-market to regulatory approval. Today, both the Food and Drug Administration and the European Medicines Agency take real-world evidence into consideration across all phases of the drug development lifecycle—and with good reason. Using RWE alongside clinical trial data can streamline time-to-insight and generate a more holistic, patient-centric view of the drug’s efficacy. 

This playbook by CorEvitas, a leading provider of gold-standard RWE, explores tactics for pharmaceutical companies looking to maximize the value of RWE during each phase of the product lifecycle. Topics include:

• Pharmaceutical research questions and clinical registry data   
• Long-term patient councils vs. one-time focus groups
• Patient insights as marketing campaign drivers

​